RESEARCH MONOGRAPH · KDC-MN-1356

PHA-543613

May 10, 2026 Kodiac biolabs Research Revised May 22, 2026 3 min read

Our opinion on this compound

55/100

Pfizer's selective alpha-7 full agonist tool compound. Useful for in vitro pharmacology, never made it to humans

PHA-543613 is one of those Pfizer-internal tool compounds that escaped into the academic research literature and became a standard reference compound for alpha-7 nicotinic pharmacology studies. It's a selective full agonist at alpha-7 with high selectivity over alpha-4-beta-2 and other nAChR subtypes, and the pharmacological profile in vitro is unusually clean. EC50 in the low nanomolar range at alpha-7, micromolar or worse at other nAChRs, and very weak activity at muscarinic receptors. That's the kind of selectivity sheet that makes pharmacologists happy.

The compound was developed by Pfizer's neuroscience team in the mid-2000s during the active alpha-7 drug discovery era, and it produced positive results in standard preclinical cognition assays (novel object recognition, social recognition memory, auditory gating tasks). The PK in rodents was reasonable, the brain penetration was good, and the mechanism work in electrophysiology preparations gave clean signal.

So why didnt PHA-543613 advance? Pfizer never put it into humans. The internal program priorities shifted, the broader alpha-7 development landscape was full of competing compounds, and PHA-543613 stayed a preclinical tool. It's been published in the academic literature mostly through external collaborators who used it as a selective alpha-7 reference compound rather than as a drug candidate.

What we like is the in vitro selectivity. For studies where you need a high-selectivity alpha-7 full agonist as a comparator or reference, PHA-543613 is one of the better-characterized options. The mechanism work in slice electrophysiology and cell-based assays is solid.

What we hedge on is everything beyond in vitro. No human data, limited in vivo work beyond standard rodent cognition assays, no published toxicology to speak of. As a tool for preclinical mechanism studies, fine. As anything beyond that, the data isnt there.

The full agonist versus partial agonist debate applies here too. PHA-543613 is a full agonist and inherits whatever theoretical limitations the full agonist strategy has at alpha-7 (desensitization concerns, narrow therapeutic window if translated). The fact that selective alpha-7 full agonists havent had clinical success generally is a relevant caveat.

Sourcing is small molecule, conventional synthesis, NMR and HPLC verification standard. Most academic suppliers deliver above 98%. For alpha-7 in vitro pharmacology with high selectivity requirements, this is a legitimate tool compound.

Evidence: 30
Mechanism: 75
Reliability: 65
Safety: 50
Sourcing: 70
Value: 60
Signal: 45
Staying power: 45

Selective alpha-7 nicotinic acetylcholine receptor full agonist (preclinical research compound)

A quinuclidine furo[2,3-c]pyridine-5-carboxamide developed at Pfizer in the mid-2000s as a brain-penetrant orally bioavailable selective alpha-7 nicotinic full agonist with substantial preclinical pharmacology in rodent cognitive models. The principal high-potency selective alpha-7 nicotinic agonist in current research use as a tool compound, with extensive use in fundamental and combination-pharmacology studies including the recent presenilin double-knockout mouse model of Alzheimer disease and synergistic combination work with memantine in aged rats.

Abstract

PHA-543613 is a small-molecule, brain-penetrant, orally bioavailable selective full agonist of the alpha-7 subtype of the neuronal nicotinic acetylcholine receptor, originated at Pfizer Global Research and Development in the mid-2000s. The chemistry was disclosed in the Wishka et al. (2006) Journal of Medicinal Chemistry report describing the structure-activity relationship study and the optimization to PHA-543613 as the lead compound from a quinuclidine-amide series. The compound binds the human alpha-7 nicotinic receptor at the orthosteric site with a Ki of approximately 8 nanomolar and acts as a full agonist with intrinsic functional activity of approximately 80 to 90 percent of the acetylcholine maximum response. Selectivity over other neuronal nicotinic subtypes is approximately 100-fold or greater. Pharmacokinetics in rodent species support oral bioavailability of approximately 50 to 70 percent and brain-to-plasma ratio of approximately 5 to 10. The compound has not been advanced to human clinical trials. The principal published preclinical pharmacology comprises rodent cognitive enhancement studies in scopolamine-induced amnesia, MK-801-induced amnesia, beta-amyloid-induced cognitive deficit, aged-rat working memory paradigms, and the recent Hijazi et al. (2023) presenilin 1 and presenilin 2 conditional double knockout mouse model of familial Alzheimer disease. Substantial recent work has characterized the synergistic combination of PHA-543613 with memantine in aged rats with the combination demonstrating greater cognitive benefit than either compound as monotherapy.

Mechanism of action

Selective orthosteric full agonism at the alpha-7 nicotinic acetylcholine receptor. Ki approximately 8 nanomolar at human alpha-7; functional intrinsic activity 80-90 percent of acetylcholine maximum (full agonist); selectivity over alpha-4-beta-2 and other neuronal nicotinic subtypes greater than 100-fold; brain penetration in rodent species supports central nervous system pharmacology at preclinical doses.

Reported research dose ranges

No human clinical doses (compound has not been advanced to clinical trials). Rodent oral 0.3-10 mg/kg twice daily; subcutaneous and intraperitoneal 0.3-3 mg/kg. Research applications: in vitro 0.1-10 micromolar.

Selected references

Wishka DG et al. Discovery of N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide, an agonist of the alpha-7 nicotinic acetylcholine receptor: structure-activity relationships. J Med Chem. 2006;49(14):4425-4436.
Hijazi Y et al. Alpha-7 nicotinic acetylcholine receptor agonist PHA-543613 improves memory deficits in presenilin 1 and presenilin 2 conditional double knockout mice. Behav Brain Res. 2023;437:114147.
Synergistic effects of memantine and alpha-7 nicotinic acetylcholine receptor agonist PHA-543613 to improve memory of aged rats. Int J Neuropsychopharmacol. 2025;28(3):pyaf014.
Sadigh-Eteghad S et al. Effect of alpha-7 nicotinic acetylcholine receptor activation on beta-amyloid induced recognition memory impairment. Possible role of neurovascular function. Acta Cir Bras. 2015;30(11):736-742.
Acker BA et al. Discovery of N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide as an agonist of the alpha-7 nicotinic acetylcholine receptor: in vitro and in vivo activity. Bioorg Med Chem Lett. 2008;18(12):3611-3615.

Read the full monograph

The full reference document covers compound identification with chemistry and synthesis, discovery and developmental history, mechanism of action across molecular targets with quantitative receptor pharmacology, comprehensive pharmacokinetics, indication-by-indication clinical evidence base, reported research dose ranges, sourcing and quality verification, reconstitution and handling, stack interaction considerations, adverse event signal, and a structured comparative assessment of five alpha-7 nicotinic acetylcholine receptor candidates judged against five competency standards. Embedded inline below; download for offline reading.

KDC-MN-1356 Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

PHA-543613

Abstract

Mechanism of action

Reported research dose ranges

Selected references

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

Selected references

Read the full monograph

Adjacent monographs